International
The Morning Science

What science found today

‹
 

News

FDA again turns back Capricor Duchenne cell therapy

BioPharma Dive · By Gwendolyn Wu ·

FDA again turns back Capricor Duchenne cell therapy

The Brief

  • The FDA again rejected Capricor's Duchenne cell therapy, deramiocel.
  • In an unusual statement, the FDA accused Capricor of "serious data integrity violations" that compromised its study findings.
  • This is the second rejection of deramiocel since 2025.

Why it matters

The case shows that regulators can reject a therapy over data integrity problems that undermine a study's findings, so the reliability of trial data is decisive for approval.

Who’s affected

  • researchers and clinicians working on Duchenne muscular dystrophy
  • biotech and drug developers

In an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.

Timeline

  1. FDA publicly accuses Capricor of serious data integrity violations and rejects deramiocel for the second time

  2. BioPharma Dive - Latest News

    FDA again turns back Capricor Duchenne cell therapy

How do you feel about this?

0 Comments